Arun Upadhyay. Cancer: An unknown territory; rethinking before going ahead. [J]. Genes & Diseases 8(5).(2021)
DOI:
Arun Upadhyay. Cancer: An unknown territory; rethinking before going ahead. [J]. Genes & Diseases 8(5).(2021) DOI: 10.1016/j.gendis.2020.09.002.
Cancer: An unknown territory; rethinking before going ahead
摘要
Abstract
Cancer is a disease of altered signaling and metabolism
causing uncontrolled division and survival of transformed cells. A host of molecules
factors
and conditions have been designated as underlying causes for the inception and progression of the disease. An enormous amount of data is available
system-wide interaction networks of the genes and proteins are generated over the years and have now reached up to a level of saturation
where we need to shift our focus to the more advanced and comprehensive methods and approaches of data analysis and visualization. Even with the availability of enormous literature on this one of the most pressing pathological conditions
a successful cure of the disease seems to be obscure. New treatment plans
like immunotherapy and precision medicine
are being employed for different studies. Nevertheless
their actual benefits to the patients would be known only after the evaluation of clinical data over the next few years. Therefore
we need to look at few fundamental challenges that should be addressed in more depth before we could devise better
rigorous
and comprehensive treatment plans and may successfully reach a possible cure of the disease. This article aims at bringing attention towards some fundamental gaps in our approach towards the disease that leads to failure in devising successful therapeutics.
关键词
Keywords
Bottom-up approachEvolution of cancerGenetic diversityImmunotherapyMultimodal treatment
Cancer organoids: A platform in basic and translational research
Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy
The link between intracellular calcium signaling and exosomal PD-L1 in cancer progression and immunotherapy
Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients
Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy
Related Author
Xin Ma
Qin Wang
Guozheng Li
Hui Li
Shouping Xu
Da Pang
Pengcheng Zhao
Longyan Xie
Related Institution
Sino-Russian Medical Research Center, Harbin Medical University Cancer Hospital
Heilongjiang Academy of Medical Sciences
Department of Breast Surgery, Harbin Medical University Cancer Hospital
Department of Pharmacology (The State-Province Key Laboratories of Biomedicine-Pharmaceutics of China), College of Pharmacy of Harbin Medical University
Tongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University